MIRM
Mirum Pharmaceuticals, Inc.
+0.13 (+0.13%)97.50USD228K成交股數6.3B市值–本益比(近四季)10.2股價營收比+37.9%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 176M+38% | 160M+43% | 149M+65% | 133M+71% | 128M+85% | 112M+60% | 90.4M+89% | 77.9M+108% | 69.2M | 69.6M | 47.7M | 37.5M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 90.5M | 97.9M | 56.1M | 43.0M | 46.1M | 41.0M | 31.7M | 32.7M | 32.2M | 30.9M | 26.1M | 22.0M |
| 銷售管理費用 | 81.5M | 96.3M | 74.1M | 61.9M | 63.3M | 57.7M | 50.5M | 49.2M | 45.6M | 46.2M | 36.5M | 32.9M |
| 營業利益 | −42.5M+753% | −789M+5100% | −4.6M-64% | 2.6M-111% | −5.0M-81% | −15.2M-53% | −12.7M-50% | −24.2M-0% | −26.5M | −32.6M | −25.1M | −24.3M |
| 營業利益率 | -24.1% | -493.8% | -3.1% | 2.0% | -3.9% | -13.6% | -14.0% | -31.1% | -38.2% | -46.8% | -52.7% | -64.7% |
| 稅後淨利 | −67.2M+1047% | −790M+5284% | −5.7M-60% | 2.9M-112% | −5.9M-77% | −14.7M-59% | −14.2M-40% | −24.6M-67% | −25.3M | −35.7M | −23.6M | −74.0M |
| 淨利率 | -38.1% | -494.2% | -3.8% | 2.2% | -4.6% | -13.2% | -15.8% | -31.6% | -36.5% | -51.3% | -49.4% | -197.5% |
| 稀釋 EPS | -1.06+783% | -13.43+4377% | -0.10-67% | 0.05-110% | -0.12-78% | -0.30-57% | -0.30-47% | -0.52-73% | -0.54 | -0.69 | -0.57 | -1.94 |
| 稀釋股數 | 63.4M | 58.9M | 50.2M | 57.0M | 49.7M | 48.9M | 47.8M | 47.2M | 46.9M | 40.9M | 41.1M | 38.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 331M | 325M | 297M | 282M | 228M | 212M | 223M | 233M | 303M | 286M | 303M | 297M |
| 應收帳款 | 145M | 133M | 123M | 107M | 107M | 95.9M | 68.5M | 60.4M | 55.0M | 68.0M | 47.8M | 35.3M |
| 存貨 | 25.8M | 25.5M | 24.9M | 24.0M | 22.9M | 22.4M | 21.6M | 20.4M | 21.6M | 22.3M | 22.3M | 8.5M |
| 總資產 | 1.0B | 891M | 843M | 785M | 726M | 690M | 668M | 661M | 652M | 647M | 651M | 444M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 1.1B | 648M | 528M | 493M | 471M | 457M | 436M | 432M | 417M | 398M | 382M | 365M |
| 股東權益 | −10.4M | 242M | 315M | 292M | 255M | 233M | 232M | 229M | 235M | 249M | 269M | 78.6M |
| 負債比 | 101.0% | 72.8% | 62.7% | 62.8% | 64.8% | 66.2% | 65.3% | 65.3% | 64.0% | 61.5% | 58.6% | 82.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −229M+11566% | – | – | – | −2.0M | – | – | 15.2M | – | – | – |
| 資本支出 | – | 664K | – | – | – | 41K | – | – | 13K | – | – | – |
| 自由現金流 | – | −229M+11360% | – | – | – | −2.0M | – | – | 15.2M | – | – | – |
| 折舊攤銷 | – | 6.9M | – | – | – | 6.1M | – | – | 5.7M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -143.5% | – | – | – | -1.8% | – | – | 22.0% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 521M
| Reportable | 521M | 100.0% | +54.7% |
|---|
產品／服務2025 年度 · 521M
| Livmarli | 360M | 69.1% | +68.8% |
|---|---|---|---|
| Bile Acid Medicines | 161M | 30.9% | +31.0% |
| 產品 小計 | 521M | 100.0% | +55.0% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 521M | +54.7% | −23.4M | -4.5% | -0.47 | 54.9M |
| FY2024 | 337M | +80.8% | −87.9M | -26.1% | -1.85 | 9.3M |
| FY2023 | 186M | +141.8% | −163M | -87.7% | -4.00 | −71.1M |
| FY2022 | 77.1M | +302.7% | −136M | -176.0% | -4.02 | −120M |
| FY2021 | 19.1M | – | −84.0M | -438.9% | -2.77 | −133M |
| FY2020 | 0.00 | – | −103M | –% | -4.09 | −89.3M |
| FY2019 | – | – | −52.6M | –% | -4.58 | −39.6M |